Core 2: Translational Biospecimens and Imaging Biomarkers

核心 2：转化生物样本和成像生物标志物

• 批准号: 10270310
• 负责人: Simona Shaitelman
• 金额: $ 29.96万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-21 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10270310
• 关键词: Algorithms; Basic Science; Biological; Biological Factors; Biological Markers; Biopsy Specimen; Blood; Brain; Cancer Center; Cancer Patient; Cardiology; Cardiopulmonary; Catalogs; Cell Line; Characteristics; Clinical; Clinical Data; Clinical Research; Clinical Trials; Collection; Consent; Data; Data Collection; Data Set; Databases; Development; Dose; Enrollment; Functional Imaging; Funding; General Hospitals; Goals; Grant; Hepatic; Human; Image; Image Analysis; Immune system; Immunologics; Immunophenotyping; Immunosuppression; In Vitro; Informed Consent; Institution; Laboratories; Logistics; Lung; Lymphocyte; Magnetic Resonance Imaging; Massachusetts; Medical; Mission; Molecular; Neuraxis; Normal tissue morphology; Oncology; Outpatients; Patient-Focused Outcomes; Patients; Photons; Physicians; Procedures; Process; Program Research Project Grants; Protein Analysis; Protocols documentation; Protons; Provider; Publications; Radiation; Radiation Oncologist; Radiation therapy; Recommendation; Research; Research Personnel; Resources; Sampling; Scientist; Secure; Site; Specimen; Standardization; Technical Expertise; Testing; Tissues; Toxic effect; Translational Research; Treatment-related toxicity; Tumor Biology; Tumor Subtype; United States National Institutes of Health; Universities; University of Texas M D Anderson Cancer Center; analysis pipeline; automated segmentation; base; cancer care; cell culture collection; circulating biomarkers; clinical care; clinically relevant; data de-identification; experience; human tissue; imaging biomarker; imaging modality; improved; in vivo; individualized medicine; innovation; interest; liver imaging; novel; participant enrollment; particle therapy; patient derived xenograft model; patient population; personalized medicine; pre-clinical research; precision medicine; prospective; proton therapy; radiation adverse effect; repository; sample collection; tissue culture

CORE 2 TRANSLATIONAL BIOSPECIMEN AND IMAGING BIOMARKER CORE SUMMARY The Translational Biospecimen and Imaging Biomarker Core Component (Core 2) is a unique, centralized resource to support biospecimen and imaging data collection from radiation-treated patients and will provide sample collection, processing, and sharing. These activities will be carried out for patients enrolled in clinical trials of experimental radiotherapy at the two partnering sites using standardized protocols and procedures. This core will 1) obtain voluntary, informed consent from oncology patients who will undergo or be evaluated for radiation therapy to allow for: (i) identification, storage, and use of patients’ blood, tissue, and clinical information for research purposes, (ii) linkage of clinical information to results from research performed on biospecimens in cooperation with core 1, (iii) sharing and publication of de-identified data generated from scientific study; 2) provide a comprehensive, secure and standardized process for collecting, annotating and storing imaging biomarkers and biological specimens from patients who have undergone, will undergo or be evaluated for radiotherapy at the Massachusetts General Hospital (MGH) and the University of Texas MD Anderson Cancer Centers (UTMDACC); and 3) facilitate the conduct of basic and translational research to further personalize therapy using imaging and blood biomarkers collected during the course of clinical care together with clinical data. Core 2 will support innovative approaches in the projects, such as multiplexed protein analyses and immunophenotyping and new imaging methods. The Core will facilitate translational biomarker studies based on understanding of intrinsic tumor biology and lymphocyte alterations following proton versus photon radiotherapy, which remains largely uncharacterized in the field of particle therapy. Moreover, supporting Project 1, the use of imaging biomarkers to gain information on the effects of proton therapy on normal tissues as a function of both dose and LET is highly innovative, as is the development of AI-based autosegmentation algorithms for MRI and XNAT image analysis pipeline, including the voxel-based analysis of functional imaging for liver, central nervous system and lung. Core 2’s support will enable novel understanding of the interaction of the immune system with proton versus photon radiotherapy in Project 2. Project 3 will rely on Core 2 to provide human tissue specimen for the creation of PDX models and a catalogue of cell lines available for preclinical research across institutions, thereby harnessing the strengths of MGH and UTMDACC. The strength of Core 2 is that it leverages the unique patient population and capabilities at the two Cancer Centers. The MGH site will contribute 20 years of expertise in circulating biomarker studies in over 40 clinical trials, while the UTMDACC site will provide extensive experience in leading nationwide multicenter collaborative proton versus photon therapy clinical and translational research that includes standardized procedures of patient enrollment, patient consent, and biospecimen collections. Both sites will also provide superb imaging biomarker study capabilities and the core will facilitate transfer of these datasets between the two centers.

芯2 翻译生物标本和成像生物标志物核心 总结 翻译生物标本和成像生物标志物核心组件（核心2）是一个独特的、集中的 资源，以支持生物标本和成像数据收集从放射治疗的病人，并将提供 样本收集、处理和共享。这些活动将针对入组临床研究的患者开展。 在两个合作地点使用标准化方案和程序进行实验性放射治疗试验。这 核心将1）从将接受或接受评估的肿瘤患者获得自愿知情同意， 放射治疗允许：（i）识别、存储和使用患者的血液、组织和临床信息 出于研究目的，（ii）将临床信息与对生物标本进行的研究结果联系起来， 与核心1合作，（三）分享和公布科学研究产生的去识别数据; 2） 提供全面、安全和标准化的流程，用于收集、注释和存储图像 来自已接受、将接受或将接受评估的患者的生物标志物和生物标本， 在马萨诸塞州总医院（MGH）和德克萨斯大学MD安德森癌症中心接受放射治疗 中心（UTMDACC）;和3）促进基础和转化研究的进行，以进一步个性化 使用在临床护理过程中收集的成像和血液生物标志物的治疗以及临床 数据核心2将支持项目中的创新方法，如多重蛋白质分析和 免疫分型和新的成像方法。核心将促进基于以下内容的翻译生物标志物研究： 了解质子与光子放射治疗后的内在肿瘤生物学和淋巴细胞变化， 这在粒子治疗领域中仍然很大程度上未被表征。此外，支持项目1，使用 成像生物标志物，以获得质子治疗对正常组织的影响的信息， 剂量和LET都是高度创新的，基于AI的MRI自动分割算法的开发也是如此 和XNAT图像分析流水线，包括基于体素的肝脏、中枢、 神经系统和肺。核心2的支持将使新的理解的相互作用的免疫 在项目2中，质子与光子放射治疗系统。项目3将依靠核心2提供人类 用于创建PDX模型的组织标本和可用于临床前研究的细胞系目录 跨机构，从而利用MGH和UTMDACC的优势。Core 2的优势在于， 利用两个癌症中心独特的患者人群和能力。MGH网站将做出贡献 在40多项临床试验中的循环生物标志物研究方面拥有20年的专业知识，而UTMDACC中心将 在领先的全国多中心协作质子与光子治疗方面提供丰富的经验 临床和转化研究，包括患者入组，患者同意， 和生物标本收集。这两个站点还将提供卓越的成像生物标志物研究能力， 核心数据库将促进两个中心之间数据集的传输。